Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Inc. ( ALMS ) saw some massive stock movement yesterday, closing at gains of 95%. This was, of course, due to some very promising results from their lead candidate, envudeucitinib. The company also saw the result announcement as a goodI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation g ...